Torrent Pharma Approves FY26 Results, Recommends ₹9 Dividend, Eyes ₹5,000 Cr QIP
Torrent Pharmaceuticals announced its FY26 results, with total revenue at ₹10,712 crore and net profit at ₹2,192 crore. The company recommended a final dividend of ₹9 per share and plans to seek approval for raising up to ₹5,000 crore via QIP. The record date for the dividend is May 29, 2026.
The announcement includes financial results, a dividend payout, and a significant fundraising plan, all of which are material events for investors.
The company reported positive financial results and recommended a dividend, indicating financial health and shareholder returns.
Torrent Pharmaceuticals Limited announced its audited financial results for the quarter and year ended March 31, 2026. The Board of Directors approved both standalone and consolidated financial results, which received unmodified audit reports. The company also recommended a final dividend of ₹9 per equity share (180%) for the financial year ended March 31, 2026.
Additionally, the Board recommended seeking enabling approval from shareholders at the upcoming Annual General Meeting (AGM) for raising funds up to ₹5,000 crore through Qualified Institutional Placement (QIP) or other modes. The record date for the proposed final dividend has been fixed as Friday, May 29, 2026, with the payment expected around June 25, 2026. An interim dividend of ₹29 per equity share was already paid during the previous quarter.
The company also provided its standalone financial highlights, reporting total revenue from operations of ₹2,735 crore for the quarter ended March 31, 2026, and ₹10,712 crore for the full year. Net profit for the quarter stood at ₹467 crore, while the full year net profit was ₹2,192 crore. The Board meeting commenced at 2:00 pm and concluded at 4:00 pm on May 22, 2026.
What to do with a filing like this
Torrent Pharmaceuticals Limited filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it high impact, which is the band that most often changes something.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Torrent Pharmaceuticals Limited. Read the original for the full detail.